Fidaxomicin is a macrocyclic antibacterial agent belonging to the tiacumicin class, primarily utilized for the treatment of Clostridioides difficile infection. By inhibiting bacterial RNA polymerase, this… Read more
![Chemical structure of (2R,3S,4S,5S,6R)-6-(((1S,4E,6E,9S,10E,12R,13E,15E,19R)-12-Ethyl-9-hydroxy-10,14,16,19-tetramethyl-3-oxo-2,18-dioxabicyclo[15.2.1]icosa-4,6,10,13,15-pentaen-4-yl)methoxy)-4-hydroxy-5-methoxy-2-methyltetrahydro-2H-pyran-3-yl 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2R3S4S5S6R-6-1S4E6E9S10E12R13E15E19R-12-Ethyl-9-hydroxy-10141619-tetramethyl-3-oxo-218-dioxabicyclo15.2.1icosa-46101315-pentaen-4-ylmethoxy-4-hydroxy-.png&w=3840&q=75)





























Fidaxomicin is a macrocyclic antibacterial agent belonging to the tiacumicin class, primarily utilized for the treatment of Clostridioides difficile infection. By inhibiting bacterial RNA polymerase, this narrow-spectrum antibiotic selectively targets pathogens while preserving the normal gut flora. The compounds in this category—including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled standards—are essential for comprehensive analytical workflows. Pharmaceutical laboratories rely on these reference standards to conduct precise impurity profiling, perform method validation, and ensure robust quality control during drug development and manufacturing. Whether identifying degradation products or quantifying fidaxomicin levels in complex matrices using stable isotope labelled analogues, these materials provide the accuracy required for regulatory compliance and safety testing. This collection supports the detailed characterization necessary for monitoring the consistency and integrity of fidaxomicin formulations.